-
Company Profile
Chemomab Therapeutics Ltd – Company Profile
Chemomab Therapeutics Ltd (Chemomab), formerly Anchiano Therapeutics Ltd, is a clinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for the unmet needs of fibrotic and inflammatory diseases. Its pipeline drug candidate is CM-101 focused on CCL24 that is advanced in PSC and SSc orphan drug indications. The company operates subsidiaries in Israel and Delaware. Chemomab is headquartered in Tel Aviv-Yafo, Tel Aviv, Israel.
Add to Basket -
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Disease – Global Clinical Trials Review, H1 2020
GlobalData's clinical trial report, “Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Global Clinical Trials Review, H1, 2020" provides an overview of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease...